Vor Biopharma
Vor Biopharma is a clinical-stage biotechnology company that holds ex-Greater China rights to telitacicept, a first-in-class dual BAFF/APRIL inhibitor licensed from RemeGen, and is advancing global Phase 3 trials in generalized myasthenia gravis and primary Sjögren's disease.
- Company typePublic
- Founded2017
- HeadquartersCambridge, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vor Biopharma does
Vor Biopharma is a clinical-stage biotechnology company headquartered in Boston, Massachusetts that develops therapies for autoimmune diseases. Originally founded in 2017 to develop CRISPR-based gene-edited stem cell therapies for hematological malignancies (CD33-deleted trem-cel for AML and MDS), the company underwent a major strategic pivot in June 2025, reducing its workforce by approximately 95% and refocusing entirely on autoimmune disease drug development following a licensing deal with RemeGen Co., Ltd. Vor Bio is publicly traded on NASDAQ under ticker VOR.
The company's core asset is telitacicept, a first-in-class TACI-Fc fusion protein that simultaneously inhibits BAFF and APRIL, two upstream B-cell survival signals that drive harmful B-cell maturation, proliferation, and autoantibody production. Under the June 2025 license worth up to $4 billion, Vor Bio holds exclusive ex-Greater China rights; RemeGen independently develops, manufactures, and commercializes the drug in China under the brand Teliain, where it has received approvals for SLE (2023), RA (2024), MG (2025), Sjögren's disease (June 2026), and IgA nephropathy (June 2026). Vor Bio is advancing two global Phase 3 trials: UPSTREAM MG (~180 patients) and UPSTREAM SjD (~250 patients), with topline MG data expected in H1 2027.
Vor Bio's business model is currently pre-commercial in the US, with no product revenue. The company generates no direct revenue from Chinese sales and is funded entirely through equity capital, having raised over $500 million in 2025-2026 to extend its cash runway into early 2029. Management is building US commercialization infrastructure under CEO Jean-Paul Kress (former MorphoSys CEO) with commercial leadership hired from Sarepta, argenx, and Vertex, targeting a future US specialty pharmacy launch contingent on FDA approval.
Vor Biopharma firmographics
Firmographics- Name
- Vor Biopharma
- Legal name
- Vor Biopharma, Inc.
- Website
- https://vorbio.com
- Company type
- Public
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Vor Biopharma is a clinical-stage biotechnology company that holds ex-Greater China rights to telitacicept, a first-in-class dual BAFF/APRIL inhibitor licensed from RemeGen, and is advancing global Phase 3 trials in generalized myasthenia gravis and primary Sjögren's disease.
- Ownership category
- akta.pro rank
Vor Biopharma industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
- akta.pro secondary industries
- Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Vor Biopharma is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Vor Biopharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Telitacicept (ex-Greater China): Vor Bio holds exclusive rights to develop and commercialize telitacicept outside Greater China. RemeGen independently developed the drug and holds responsibility for development, regulatory approvals, and commercialization within China. Vor Bio is advancing global Phase 3 trials for myasthenia gravis and Sjögren's disease toward potential US FDA approval and commercial launch.
- RemeGen licensing and warrant stake: The June 2025 licensing deal with RemeGen included $45 million upfront plus warrants giving a RemeGen subsidiary a 23% stake in Vor Bio. This creates a financial alignment where Vor's success directly benefits RemeGen shareholders.
- Tens of thousands of patients treated commercially in China: Telitacicept (marketed as Teliain in China by RemeGen) is already commercially approved and generating revenue in China across SLE, RA, MG, Sjögren's disease, and IgA nephropathy, with tens of thousands of patients treated. Vor receives no direct commercial revenue from China sales but benefits from the large real-world safety and efficacy dataset.
Go-to-market motion3 records
Distribution channels2 records
Marketing channels5 records
Vor Biopharma product offering
Product offeringCore offering
Vor Biopharma is a clinical-stage biotechnology company developing telitacicept, a first-in-class TACI-Fc fusion protein that simultaneously inhibits BAFF and APRIL signaling pathways to treat autoimmune diseases. The company holds ex-Greater China rights licensed from RemeGen and is advancing global Phase 3 trials in generalized myasthenia gravis (UPSTREAM MG) and primary Sjögren's disease (UPSTREAM SjD), while the drug is already commercially approved in China for SLE, RA, and MG.
Product overview
Vor Biopharma is a clinical-stage biotechnology company focused on advancing telitacicept, a potential best- and first-in-class dual BAFF/APRIL inhibitor (TACI-Fc fusion protein) for autoimmune diseases. The company's portfolio centers on telitacicept, which has been approved in China for three autoimmune indications (SLE, RA, MG) with additional approvals pending. Global Phase 3 trials are underway for generalized myasthenia gravis (UPSTREAM MG) and Sjögren's disease (UPSTREAM SjD). Telitacicept works by blocking BAFF and APRIL signals that sustain harmful B cells, reducing autoantibody production and restoring immune balance.
Differentiator
Problem solved
Functional benefit
Products and services
- Telitacicept A first-in-class dual BAFF/APRIL inhibitor (TACI-Fc fusion protein) designed to rebalance immunity by silencing signals that drive harmful B-cell maturation, proliferation, and survival, thereby reducing autoantibody production in autoimmune diseases. Vor Bio holds ex-Greater China development and commercialization rights.
Quantifiable outcome
- 58.9-59% reduction in urinary protein-to-creatinine ratio (UPCR) in IgA nephropathy patients at Week 39 in Phase 3 TELIGAN trial
- +4 more outcomes
Companies that use Vor Biopharma
Customer profileSegments1 record
Ideal customer profiles2 records
Vor Biopharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Vor Biopharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- RemeGen Co., Ltd.coreVor Bio entered a licensing agreement with RemeGen worth up to $4 billion for ex-Greater China rights to telitacicept, a dual BAFF/APRIL inhibitor for autoimmune diseases. The deal included $45 million upfront plus warrants giving a RemeGen subsidiary a 23% stake in Vor. RemeGen independently develops, manufactures, and commercializes telitacicept in China, where it holds multiple approvals for autoimmune diseases including SLE, RA, MG, Sjögren's disease, and IgA nephropathy.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Vor Biopharma competitors and assessment
Company assessmentDirect peers
- argenx: Commercial-stage autoimmune biotech with efgartigimod (VYVGART), an FcRn antagonist approved for generalized myasthenia gravis — the same lead indication as Vor's UPSTREAM MG Phase 3 program. Directly comparable business model (clinical-to-commercial autoimmune biotech) and target patient population.
- RemeGen: Chinese biotech that developed telitacicept and is Vor Bio's licensing partner. Holds Chinese commercial rights and manufactures the drug; directly comparable asset (telitacicept itself) and overlapping autoimmune disease focus.
Broad incumbents
- MorphoSys: Specialty immunology biotech commercializing Monjuvi (tafasitamab) in lymphoma and pipeline assets in autoimmune disease — recently acquired by Novartis. Comparable as an autoimmune/hematology-focused biotech; Vor Bio's CEO Jean-Paul Kress was previously MorphoSys CEO.
- Sarepta Therapeutics: Commercial-stage biotech with multiple rare disease product launches. Vor Bio's CCO Dallan Murray was previously EVP/CCO at Sarepta; comparable as a rare/specialty disease launch and commercialization platform.
- Bristol Myers Squibb: Major pharma with extensive autoimmune franchise including Zeposia (SjD/MS), deucravacitinib, and several lupus/RA assets. Competes with Vor Bio's telitacicept pipeline across multiple overlapping indications including SLE and SjD.
- AbbVie: Major autoimmune franchise with Humira, Rinvoq, and Skyrizi across RA, lupus, and other indications. Vor Bio's CMAO Navid Khan previously led immunology translational science at AbbVie; broad competitive overlap in autoimmune disease.
- AstraZeneca: Major pharma with autoimmune pipeline including anifrolumab (SLE) and several immunology assets. Competes across multiple of Vor Bio's target indications including lupus, RA, and rare autoimmune diseases.
- Sanofi: Major pharma with autoimmune franchise including Dupixent and multiple B-cell targeting programs. Vor Bio CEO Jean-Paul Kress serves on Sanofi's board. Competes broadly in immunology and rare autoimmune disease.
Emerging players
- UCB: Specialty immunology company with rozanolixizumab (Rystiggo) approved for generalized myasthenia gravis — directly competing with Vor's UPSTREAM MG program. Comparable focus on Fc receptor and B-cell pathway modulators in autoimmune neurology.
Others
- Vertex Pharmaceuticals: Major biotech with growing autoimmune/inflammation franchise. Vor Bio's CCO Dallan Murray previously led Vertex's INCIVEK launch — the fastest biotech launch to $1B at the time. Comparable as a high-growth specialty biotech with strong commercial execution.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Vor Biopharma social profiles
Digital presenceVor Biopharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vor Biopharma leadership team
Management profileNumber of profiles
Profiles7 records
Vor Biopharma funding detail
Funding detailFunding overview
Funding rounds8 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vor Biopharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vor Biopharma
What does Vor Biopharma do?
Vor Biopharma is a clinical-stage biotechnology company developing telitacicept, a first-in-class TACI-Fc fusion protein that simultaneously inhibits BAFF and APRIL signaling pathways to treat autoimmune diseases. The company holds ex-Greater China rights licensed from RemeGen and is advancing global Phase 3 trials in generalized myasthenia gravis (UPSTREAM MG) and primary Sjögren's disease (UPSTREAM SjD), while the drug is already commercially approved in China for SLE, RA, and MG.
Is Vor Biopharma a public or private company?
Vor Biopharma is a public company. It is classified as public and is currently operating.
When was Vor Biopharma founded?
Vor Biopharma was founded in 2017. It employs 101 to 250 people.
Where is Vor Biopharma based?
Vor Biopharma is headquartered in Cambridge, United States, in the North America region.
How does Vor Biopharma make money?
Three revenue lines are on record. Telitacicept (ex-Greater China) is the primary driver. The others are remeGen licensing and warrant stake and tens of thousands of patients treated commercially in China.
Who are Vor Biopharma's main competitors?
Direct peers on record are argenx and RemeGen. Broad incumbents are MorphoSys, Sarepta Therapeutics, Bristol Myers Squibb, AbbVie, AstraZeneca and Sanofi. UCB is listed as an emerging player. Vertex Pharmaceuticals is listed as an others.
Does Vor Biopharma have an API?
No public API is recorded for Vor Biopharma.
What industry is Vor Biopharma in?
Vor Biopharma's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies. Its NAICS code is 541714 and its SIC code is 2834.